Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

– July 1, 2012

July 1, 2012

View Archives Issues

  • Cancer Prevention by Aspirin: A New Evaluation of Existing Data

    By a systematic review of observational (case-control and cohort) studies, data regarding aspirin use and cancer risk were compared to data obtained from randomized clinical trials. In general, there was very good correlation regarding reduced risk for several types of cancer and the development of metastatic disease. The analysis provides confidence that observational studies can be of value in addressing the many outstanding questions regarding aspirin and cancer prevention.
  • Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy

    In a large retrospective series, 2051 men with clinically localized prostate cancer received definitive radiation therapy (RT) alone. The rates of aspirin use and statin use were 36% and 34%, respectively. The primary endpoint was IBF (interval to biochemical failure) of < 18 months.
  • Controlling Pegfilgrastim Bone Pain

    This randomized, placebo-controlled, Phase 3 clinical trial showed that the majority of patients treated with pegfilgrastim experience bone pain, and that taking 500 mg of naproxen twice a day decreases its incidence and severity.
  • Monoclonal Gammopathy of Undetermined Significance

    A 64-year-old commercial airline pilot was seen by his primary physician because of a bothersome, non-productive cough. He has a history of asthma but requires no medications other than occasional albuterol inhalation. Physical examination was unremarkable, as were the complete blood count and chest x-ray.
  • Diabetes as a Risk Factor for Hematologic Malignancy

    In a meta-analysis of current observational (both case-control and prospective cohort) studies evaluating the potential association between type 2 diabetes mellitus and the incidence of hematological malignancy, an increased risk for non-Hodgkin lymphoma and leukemia was demonstrated as well as a trend toward an increased risk for myeloma. Confounding factors such as age, obesity, smoking, and alcohol (risks for both diabetes and malignancy) could not be completely accounted for in such an analysis.
  • Clinical Briefs in Primary Care Supplement

  • Pharmacology Watch

    Azithromycin and cardiac risk; warfarin and heart failure; aspirin and VTE; effectiveness of long-acting contraceptives; and FDA actions.